Sara Nunnery, MD, MSCI

Sara Nunnery, MD, MSCI, is a medical oncologist with Tennessee Oncology.

Articles by Sara Nunnery, MD, MSCI

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

BySara Nunnery, MD, MSCI,Megan Kruse, MD

June 30th 2026

Drs Nunnery and Kruse discuss the controversy surrounding a biomarker-driven switch strategy in hormone receptor–positive, HER2-negative breast cancer.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; Vandana G. Abramson, MD, professor, medicine, co-leader, Breast Cancer Research Program, Breast Cancer Disease Team leader, Vanderbilt Health and the Vanderbilt-Ingram Cancer Center

Oral SERDs Transform Metastatic Breast Cancer Management: With Sara Nunnery, MD, MSCI; and Vandana G. Abramson, MD

BySara Nunnery, MD, MSCI,Vandana G. Abramson, MD

June 16th 2026

Nunnery and Abramson discussed the transformative effects of next-generation oral SERDs in hormone receptor–positive breast cancer management.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; Annie Bond, breast cancer survivor, patient advocate

Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond

BySara Nunnery, MD, MSCI,Annie Bond

May 12th 2026

Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.

Sara Nunnery, MD, MSCI, Tennessee Oncology; Irene Morae Kang, MD, City of Hope Orange County

ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD

BySara Nunnery, MD, MSCI,Irene Morae Kang, MD

April 30th 2026

Drs Nunnery and Kang discuss the rapidly evolving treatment paradigm for first-line metastatic TNBC, including the emergence of novel ADCs.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology in Nashville; Neil M. Iyengar, MD, associate professor, co-director, Breast Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, director, Survivorship Services, Winship Cancer Institute of Emory University

Evolving Research Puts a Focus on GLP-1 Agonist Use in Breast Cancer: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

BySara Nunnery, MD, MSCI,Neil Iyengar, MD

April 16th 2026

Drs Nunnery and Iyengar highlight the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

BySara Nunnery, MD, MSCI,Neil Iyengar, MD

April 2nd 2026

Drs Nunnery and Iyengar discuss lifestyle and medical interventions pertinent to breast cancer survivorship.

Kelly E. McCann, MD, PhD, breast medical oncologist, University of California system; Sara Nunnery, MD, MSCI, breast medical oncologist, Tennessee Oncology

T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD

BySara Nunnery, MD, MSCI,Kelly E. McCann, MD, PhD

March 26th 2026

Drs Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm.

The Future of ADCs: Earlier Use, Smarter Selection, and Adaptive Care

ByKamel Abou Hussein, MD,Sara Nunnery, MD, MSCI

March 20th 2026

Clinicians debate sequencing breast cancer ADCs, weighing back‑to‑back use vs chemo breaks, and managing ILD, nausea, fatigue, cardiotoxicity.

Sequencing ADCs and Managing Cumulative Toxicity

ByKamel Abou Hussein, MD,Sara Nunnery, MD, MSCI

March 20th 2026

How doctors sequence ADCs, pick the best first option, and manage T-DXd ILD, nausea and fatigue in metastatic breast cancer.

ADC–Immunotherapy Combinations in PD-L1–Positive and Future Directions

ByKamel Abou Hussein, MD,Sara Nunnery, MD, MSCI

March 13th 2026

ASCENT-04 shows SG plus pembrolizumab boosts PFS without extra toxicity in PD-L1+ TNBC, while trials test IO for PD-L1− disease.

First-Line ADC Options in Metastatic Triple-Negative Breast Cancer

ByKamel Abou Hussein, MD,Sara Nunnery, MD, MSCI

March 13th 2026

New trials redefine HER2 ultra-low disease, guiding when to use T-DXd vs oral chemo and emerging Trop-2 ADC options.

Leading Breast Oncologists Share Advice and Optimism for Future Women in Oncology: With Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI

ByKelly E. McCann, MD, PhD,Sara Nunnery, MD, MSCI

March 8th 2026

Drs McCann and Nunnery share their stories and perspectives as leading women in oncology in honor of International Women's Day.

Expanding ADC Use in HER2-Low Hormone Receptor–Positive Disease

ByKamel Abou Hussein, MD,Sara Nunnery, MD, MSCI

March 6th 2026

DB-06 reshapes HER2 testing with ultra-low disease, guiding T-DXd timing and comparing Trop-2 ADC options by toxicity and survival data.

Moving ADCs to the Frontline in Metastatic HER2-Positive Disease

ByKamel Abou Hussein, MD,Sara Nunnery, MD, MSCI

March 6th 2026

New first-line TDxd plus pertuzumab reshapes HER2+ metastatic care, doubling PFS and sparking debate on maintenance and CNS control.

Individualizing Neoadjuvant and Adjuvant ADC Strategies

ByKamel Abou Hussein, MD,Sara Nunnery, MD, MSCI

February 27th 2026

Explore risk‑adapted T‑DXd use in early HER2+ breast cancer—who benefits, how to sequence therapy, and ILD monitoring hurdles.

ADCs Transforming Early-Stage HER2-Positive Care

ByKamel Abou Hussein, MD,Sara Nunnery, MD, MSCI

February 27th 2026

Emerging trials show trastuzumab deruxtecan boosts pCR and disease-free survival in early HER2-positive breast cancer, reshaping neoadjuvant/adjuvant care with ILD monitoring.

Sara Nunnery, MD, MSCI

Articles by Sara Nunnery, MD, MSCI

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

Oral SERDs Transform Metastatic Breast Cancer Management: With Sara Nunnery, MD, MSCI; and Vandana G. Abramson, MD

Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond

ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD

Evolving Research Puts a Focus on GLP-1 Agonist Use in Breast Cancer: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD

The Future of ADCs: Earlier Use, Smarter Selection, and Adaptive Care

Sequencing ADCs and Managing Cumulative Toxicity

ADC–Immunotherapy Combinations in PD-L1–Positive and Future Directions

First-Line ADC Options in Metastatic Triple-Negative Breast Cancer

Leading Breast Oncologists Share Advice and Optimism for Future Women in Oncology: With Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI

Expanding ADC Use in HER2-Low Hormone Receptor–Positive Disease

Moving ADCs to the Frontline in Metastatic HER2-Positive Disease

Individualizing Neoadjuvant and Adjuvant ADC Strategies

ADCs Transforming Early-Stage HER2-Positive Care

Latest Updated Articles

Trending on OncLive

Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA

Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma

Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma

FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification